CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 43 enrolled
Drug / intervention
drotrecogin alfa (activated)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00279214
NCT00279214Phase 4Completed
CompareCT.gov

An Evaluation of Vasopressor Requirement, Hemodynamic Response and Measures of Tissue Perfusion With the Administration of Drotrecogin Alfa (Activated) as Part of Physician-Directed Therapy in Patients With Septic Shock

Eli Lilly and Company·interventional·Posted Jan 19, 2006·Updated Sep 2, 2009

In Brief

A Phase 4 clinical trial evaluating drotrecogin alfa (activated) for Sepsis and Septic Shock. Completed, enrolled 43 participants across 2 sites.

Detailed Summary

The study will evaluate the vasopressor requirement, hemodynamic response and measures of tissue perfusion in patients with septic shock receiving an infusion of drotrecogin alfa (activated) compared to patients not receiving drotrecogin alfa (activated).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSepsis, Septic Shock
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 19, 2006
Enrollment StartNov 1, 2005
Study CompletionNov 1, 2007
TodayJul 2, 2026
Posted 20.5 years ago

Interventions

drotrecogin alfa (activated)drug